TempoStemBank™-iPSC: Human iPSC Stem Cell Lines

In stock

TempoStemBank™-iPSC: human iPSC lines are derived from human dermal/fibroblasts, blood or cord blood, using our proprietary genetic/viral-elements-free, nucleic-acids-free, feeder-free, and serum-free reprogramming technology. The cells express canonical biomarkers of iPSCs (e.g., Oct4, Tra-1-60, Tra-1-81, Sox2, Nanog, and SSEA-4); they have been proven to be multipotent and are able to differentiate into ectoderm, endoderm and mesoderm derivative cell types. Please inquire for ready-to-ship low passage iPSCs (Free cell culture media included!). 

Check out our new citations! 

Academic scientists receive a special rate! Ask about our Bulk Order promotions!

TempoStemBank™-iPSC: human iPSC lines are derived from human dermal/fibroblasts, blood or cord blood cells, using our proprietary virus-free, nucleic-acids-free, serum-free, and feeder-free technology. The cells express canonical biomarkers of iPSCs (e.g., e.g., Oct4, Tra-1-60, Tra-1-81, Sox2, Nanog, and SSEA-4); they have been proven to be multipotent and are able to differentiate into ectoderm, endoderm and mesoderm derivative cell types such as glial, neurons, osteoblasts, and hepatocytes.

Please email Tempo Support for Ready-to-Ship low passage iPSCs from a variety of donor samples (Free cell culture media for Academic Scientists). 

Academic scientists receive a special rate! Ask about our Bulk Order promotions!

Frequently Requested Disease Models for iPSC lines or iPS-derived cell types in the ectoderm, endoderm, and mesenchymal lineages:

  • Frontotemporal Dementia (FTD)
  • Familial Alzheimer's Disease (FAD; early onset; late onset)
  • Parkinson's Disorder (PD)
  • Multiple Sclerosis (MS)
  • Seizure Disorders (e.g., Epilepsy)
  • Motor Neuron Diseases (e.g., ALS, PLS)
  • Duchenne Muscular Dystrophy (DMD)
  • Spinal Muscular Atrophy (SMA Types I-IV)
  • Friedreich's Ataxia
  • Cardiomyopathy (e.g., Fabry Disease, Primary arrhythmias)
  • Muscular Dystrophy with Early Contractures and Cardiomyopathy
  • Emery-Dreifuss Muscular Dystrophy (EDMD)
  • Osteogenesis Imperfecta
  • Tourette Syndrome
  • Ataxia-Telangiectasia
  • Huntington Disease
  • Williams Syndrome
  • Spinocerebellar Ataxia
  • Warfan Syndrome
  • Affective Disorders (e.g., Bipolar Disorder, Depression.)
  • Schizophrenia
  • Sensory Neuropathy
  • Diabetes (Types: Familial, Juvenile Onset, or Maturity Onset)
  • Fragile X Syndrome
  • Fabry Disease
  • Angelman's Syndrome
  • Trisomy 21 (Down Syndrome)
  • Turner Syndrome
  • Sickle Cell Anemia (& carriers)
  • Turcot Syndrome
  • Osteoporosis
  • Paget Disease of Bone
  • Rheumatoid arthritis
  • Bernard-Soulier Syndrome (Giant Platelet Syndrome)
  • Von Hippel-Lindau Syndrome (VHL)
  • Chronic Kidney Diseases
  • Prader-Willi Syndrome (PWS)
  • Charcot-Marie-Tooth Disease
  • Cancer iPSCs (e.g., osteosarcoma, ovarian tumors, colorectal, neuroblastoma, glioblastoma multiforme (GBM), renal cell carcinoma (RCC), head-and-neck)
  • Ethnically Diverse Donors' Derived iPSCs 
  • Please send inquiry to Tempo Support


  • Disease modeling and drug discovery (iPSCs: grown as monolayers vs. colonies)
  • Developmental and lineage differentitation studies
  • High Content Screening (e.g., expression of differentiation markers)
  • Scalable for BioBanking (GMP-grade possible. Please send inquiry to Tempo Support)

Growth Reagents (Suggested):

  • Matrigel hESC-qualified matrix (Corning)
  • 10μM Y-27632 ROCK inhibitor (Sigma)
  • Accutase, for passaging cells (Innovative Cell Technologies)

TempoStemBank™-iPSC Lines and Disease Models

Characterizations performed:

  • biomarkers confirmation (e.g., Oct4, Tra-1-60, Tra-1-81, Sox2, Nanog, and SSEA-4);
  • functional assay (upon request);
  • multi-lineage confirmations (upon request);
  • karyotype testing (upon request);

Technology used: in-house developed proprietary nucleic-acids-free, genetic/viral-elements-free, serum-free, and feeder-free technology.

Deliverables: >0.5-6.0x10^6 cells (multiple lines or scale-up possible. Please send inquiry to Tempo Support).  BioSafety Level 2.

SKU1002: Please email Tempo Support for ready-to-ship low passage iPSCs. Academic scientists receive a special rate!

We ship worldwide.


1) Enhanced Astrocyte Responses are Driven by a Genetic Risk Allele Associated with Multiple Sclerosis

2) The Genetic Multiple Sclerosis (MS) Risk Variant rs7665090-G Increases Astrocyte Responses and Lymphocyte Recruitment to White Matter Lesions.

3) Human Cortex Spheroid with a Functional Blood Brain Barrier for High-Throughput Neurotoxicity Screening and Disease Modeling

4) Cell Sources and Methods for Producing Organotypic in vitro Human Tissue Models

5) Probing Prodrug Metabolism and Reciprocal Toxicity with an Integrated and Humanized Multi-Tissue Organ-on-a-Chip Platform

6) Cross-talk between microglia and neurons regulates HIV latency

7) Multicellular 3D Neurovascular Unit Model for Assessing Hypoxia and Neuroinflammation Induced Blood-Brain Barrier Dysfunction

8) Transport of ultrasmall gold nanoparticles (2 nm) across the blood–brain barrier in a six-cell brain spheroid model

9)  Patient-Derived Orthotopic Xenografts and Cell Lines from Pediatric High-Grade Glioma Recapitulate the Heterogeneity of Histopathology, Molecular Signatures, and Drug Response. 

10) βA1-crystallin regulates glucose metabolism and mitochondrial function in mouse retinal astrocytes by modulating PTP1B activity.

11) Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma

12) Advanced In Vitro Lung Models for Drug and Toxicity Screening: The Promising Role of Induced Pluripotent Stem Cells

More Information
Product Use TempoStemBank™-iPSC are intended for basic scientific research, drug discovery, and therapeutics development use only. It is not a product for human testing, therapeutics, or diagnostics.